Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Felip
MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression From a Phase 1/2 Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) With Oncogenic Driver Mutations: New Results From the Global IMMUNOTARGET Registry
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA12.01 Phase II Data for the MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14-Skipping Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.16-03 CheckMate 816: A Phase 3 Trial of Neoadjuvant Nivolumab Plus Ipilimumab or Chemotherapy vs Chemotherapy in Early-Stage NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
OA06 Tepotinib in Non-Small Cell Lung Cancer With MET Exon 14-Skipping Mutations or MET Amplification: A Phase 2 Trial in Progress
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P13 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- Or Erlotinib-Treated Patients With SCC of the Lung
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) With Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
1
2
›
